OMEROS CORP Payments of Debt Issuance Costs
OMEROS CORP (OMER) reported Payments of Debt Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-12
- OMEROS CORP payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00.
- OMEROS CORP payments of debt issuance costs for the quarter ending 2024-09-30 was $0.00.
- OMEROS CORP payments of debt issuance costs for the quarter ending 2020-12-31 was $0.00.
- OMEROS CORP payments of debt issuance costs for fiscal 2020 was $6.79M.
- OMEROS CORP payments of debt issuance costs for fiscal 2018 was $6.80M.
- OMEROS CORP payments of debt issuance costs for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- OMEROS CORP payments of debt issuance costs for fiscal 2016 was $1.50M, a 244.27% increase from fiscal 2015.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.84M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $2.84M 10-Q · filed 2026-08-12 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $6.79M 10-K · filed 2023-03-13 | ||
| 2020-09-30 | $6.79M 10-Q · filed 2021-11-09 | |||
| 2018-12-31 | $6.80M 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $1.50M 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $436.00K 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $244.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |